Source: Eur Respir J, 53 (3) 1900283; 10.1183/13993003.00283-2019
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Paul J. Wolters, Vincent Cottin. Molecular endpoints for establishing target engagement by novel idiopathic pulmonary fibrosis therapies. Eur Respir J, 53 (3) 1900283; 10.1183/13993003.00283-2019

Member's Comments

No comment yet.

Related content which might interest you: Potential new biomarkers for idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery Source: Eur Respir Rev 2013; 22: 148-152 Year: 2013 Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential Source: Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017 Year: 2017 Idiopathic pulmonary fibrosis: present understanding and future options Source: Eur Respir Rev 2011; 20: 132-133 Year: 2011 The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 29 (157) 200269; 10.1183/16000617.0269-2020 Year: 2020 Possible target genes in idiopathic pulmonary fibrosis Source: Annual Congress 2007 - PG9 - Molecular pathology and genetics in lung diseases Year: 2007 Accelerated variant of idiopathic pulmonary fibrosis: clinical and molecular behaviour Source: Eur Respir J 2007; 30: Suppl. 51, 488s Year: 2007 Validation of a novel prognostic tool for idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease I Year: 2012 Evaluation of recently validated non-invasive formula using basic lung functions as a new screening tool for pulmonary hypertension in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Fibrocytes: potential new therapeutic targets for pulmonary hypertension? Source: Eur Respir J 2010; 36: 1232-1235 Year: 2010 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches Source: Eur Respir J 2006; 28: 463-465 Year: 2006 Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis Source: Eur Respir Rev 2012; 21: 48-56 Year: 2012 The clinical relevance of autoimmunity in idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease II Year: 2012 Evolving concepts in the early and accurate diagnosis of idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Evolving concepts in the early and accurate diagnosis of idiopathic pulmonary fibrosis Year: 2010 Evaluation of novel LOXL2-selective inhibitors in models of pulmonary fibrosis Source: International Congress 2017 – Cellular signalling pathways in pulmonary fibrosis Year: 2017